secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapsoVision, Inc (CV)
CIK:        0001378325
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001378325-26-000004
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CapsoVision closes $14M private placement; reports preliminary FY2025 revenue of $13.6M
--------------------------------------------------------------------------------

- Raised $14M gross via 2.87M shares at $4.883 (5% discount to March 16 close); closed March 16, 2026.
- Preliminary Q4 2025 revenue $3.9M; full-year 2025 revenue $13.6M; cash & equivalents ~$10.1M as of Dec. 31, 2025.
- Abandoned first-gen CapsoCam Colon 510(k); prioritizing second-gen with improved imaging; pivotal study enrolling ~800 patients; over 500 enrolled; expects 510(k) submission in Q3 2026.
- Breakthrough Device Designation for CapsoCam UGI denied in Jan 2026; plans to resubmit after ~90-patient study starting Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/0001378325-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/cv-20260320.htm
  HTML page:      https://secwatch.observer/filing/0001378325-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer